Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BU64
UPID:
CENPO_HUMAN
Alternative names:
Interphase centromere complex protein 36
Alternative UPACC:
Q9BU64; B2RDC0; D6W536; Q53T55; Q96JV3
Background:
Centromere protein O, also known as Interphase centromere complex protein 36, plays a crucial role in chromosome segregation during cell division. It is a component of the CENPA-CAD complex, essential for the assembly of kinetore proteins, mitotic progression, and chromosome segregation. This protein is key in incorporating newly synthesized CENPA into centromeres, interacting with the CENPA-NAC complex and modulating the kinetochore-bound levels of the NDC80 complex.
Therapeutic significance:
Understanding the role of Centromere protein O could open doors to potential therapeutic strategies.